INPP5D and early-onset autosomal dominant Alzheimer disease: Most of the clinical research is focused on pharmacological substances such as inhibitors or activators that affect the catalytic activity of SHIP, which may be used in the treatment of leukemia, type 2 diabetes, and Alzheimer’s disease, as well as in patients with cystitis-induced bladder pain.